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Abstract
Background: To describe common type 2 diabetes treatment intensification regimens, patients’ characteristics and
changes in glycated hemoglobin (HbA1c) and body mass index (BMI).
Methods: We constructed a national retrospective cohort of veterans initially treated for diabetes with either
metformin or sulfonylurea from 2001 through 2008, using Veterans Health Administration (VHA) and Medicare data.
Patients were followed through September, 2011 to identify common diabetes treatment intensification regimens.
We evaluated changes in HbA1c and BMI post-intensification for metformin-based regimens.
Results: We identified 323,857 veterans who initiated diabetes treatment. Of these, 55 % initiated metformin, 43 %
sulfonylurea and 2 % other regimens. Fifty percent (N = 89,057) of metformin initiators remained on metformin
monotherapy over a median follow-up 58 months (interquartile range [IQR] 35, 74). Among 80,725 patients who
intensified metformin monotherapy, the four most common regimens were addition of sulfonylurea (79 %),
thiazolidinedione [TZD] (6 %), or insulin (8 %), and switch to insulin monotherapy (2 %). Across these regimens,
median HbA1c values declined from a range of 7.0–7.8 % (53–62 mmol/mol) at intensification to 6.6–7.0 %
(49–53 mmol/mol) at 1 year, and remained stable up to 3 years afterwards. Median BMI ranged between 30.5
and 32 kg/m2 at intensification and increased very modestly in those who intensified with oral regimens, but
1–2 kg/m2 over 3 years among those who intensified with insulin-based regimens.
Conclusions: By 1 year post-intensification of metformin monotherapy, HbA1c declined in all four common
intensification regimens, and remained close to 7 % in subsequent follow-up. BMI increased substantially for
those on insulin-based regimens.
Keywords: Diabetes mellitus type 2, Patterns of care, Clinical effectiveness, treatment intensification,
Adherence, Clinical outcomes
Background
Metformin, a biguanide approved and marketed in the
U.S. since 1995, is the preferred oral hypoglycemic medi-
cation for initial management of type 2 diabetes [1–4].
In 2006, after review of available evidence, the consensus
statement by the American Diabetes Association and the
European Association for the Study of Diabetes
recommended lifestyle modification and metformin as
the preferred first line therapies for type 2 diabetes,
with a treatment goal being glycated hemoglobin (HbA1C)
of ≤7 %. This recommendation was based on evidence
from the United Kingdom Prospective Diabetes Study
which demonstrated that those randomized to metformin
experienced 42 % fewer diabetes-related deaths and
36 % fewer all-cause deaths compared to the diet alone
arm [5, 6].
Despite consensus on initial diabetes treatment, when
to intensify and the preferred specific treatment regimen
remains highly patient specific. Diabetes treatment
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guidelines have advocated for a shared approach between
provider and patient when choosing both the treatment
goals and regimen for intensification [7]. A number of fac-
tors influence providers to recommend a medication
for intensification including medication costs, side ef-
fects, their own knowledge and beliefs about future
treatment benefits, such as prevention or delay of
macrovascular and microvascular disease [8]. Patients’
understanding of their illness, adherence to their treat-
ment regimens, and ability to manage medications also
affect decision-making about treatment choices [9, 10].
Finally, health system factors including achievement of
performance metrics can drive the decision to intensify
therapy [11, 12]. Although many experts recommend titra-
tion of therapy to reach HbA1c goals of <7 %, VHA uses
an algorithm which determines an individual glycemic
target based on consideration of microvascular compli-
cations and co morbid illness (Table 1) [13]. The guide-
lines note multiple treatment options as acceptable
add-on medications. Oral medications in general are
easier to initiate, but insulin dose can be modified in
response to daily variation in food intake, exercise or
other variables that cause daily fluctuation in glucose
values. Because of the potential microvascular benefit
to patients with tighter glycemic control, there has
been a fairly substantial increase in the use of insulin
over time [14].
Given the varied options available for add-on treat-
ment after metformin, and the use of differing HbA1c
goals for intensification, variation in clinical practice is
likely to result. Little is known about the current clinical
practice patterns for patients who fail initial diabetes
treatment. Given the recent increase in early insulin use
our aim was to describe common treatment intensifica-
tion patterns after metformin monotherapy, the charac-
teristics of patients prescribed specific regimens and
changes in glycated hemoglobin (HbA1c) and body mass
index (BMI) post-intensification.
Methods
Study design and data sources
We assembled a retrospective cohort of patients seen in
Veterans Health Administration (VHA) facilities who
had a new hypoglycemic prescription between October
1, 2001 and September 30, 2008 [15, 16]. Patients were
considered new-users of a hypoglycemic medication if
they had evidence of VHA healthcare utilization in the
previous year, and had not filled any oral or injectable
diabetic drug within the past 180 days according to a
new user design [17].
VHA pharmacy data identified dispensed prescriptions,
including medication name, date filled, days supplied, pill
or vial number and dosage [18]. VHA medical datasets
containing demographic data and ICD9-CM coded diag-
nostic and procedure information identified inpatient and
outpatient encounters [19]. Laboratory test results were
collected from standard VHA clinical sources. Vital signs
data included all outpatient measurements of height,
weight and blood pressure. For Medicare or Medicaid
enrollees, we obtained supplemental encounter, prescrip-
tion (Part D) and race data from the Centers for Medicare
and Medicaid Services through VHAs interagency ex-
change agreement [20, 21]. We obtained dates of death
from VHA vital status files. The institutional review
boards of Vanderbilt University and the VHA Tennessee
Valley Healthcare System approved this study with a waiver
of informed consent.
Study population, treatment initiation and intensification
The study population comprised veterans ≥18 years old
who filled a prescription for a hypoglycemic medication
after at least 180 days without any oral or injectable dia-
betic drug fill (new-users), and who received regular
VHA care (VHA encounter or prescription fill at least
twice in the past 365 days) [17]. Thus, veterans were re-
quired to have at least 365 days of available baseline data
preceding their first eligible medication fill. The date of
Table 1 Veterans Health Administration and Department of Defense Clinical Practice Guideline for the management of Diabetes–
Glycemic targets [13]
Comorbiditya or Physiologic age Microvascular complicationsb
Absent/Mild Moderate Advanced
Absent <7 % <8 % 8–9 %
Life expectancy >10 years (<53 mmol/mol) (<64 mmol/mol) (64–75 mmol/mol)
Comorbidity present <8 % <8 % 8–9 %
Life expectancy 5–10 years (<64 mmol/mol) (<64 mmol/mol) (64–75 mmol/mol)
Multi Comorbidities 8–9 % 8–9 % 8–9 %
Life expectancy <5 years (64–75 mmol/mol) (64–75 mmol/mol) (64–75 mmol/mol)
aComorbidity includes, but is not limited to, any or several of the following conditions: cardiovascular disease, chronic kidney disease, chronic obstructive
pulmonary disease, liver disease, stroke, and malignancy
bMicrovascular disease includes complications of diabetes: retinopathy, nephropathy (micro or macroalbuminuria) and neuropathy
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the qualifying first hypoglycemic medication fill was
considered time zero (t0). We categorized patients based
on the two most common initial treatments: metformin
and sulfonylurea.
We followed all new-users of metformin from t0 through
the prescription of another agent. Treatment intensifica-
tion, termed t1, to the initial regimen was defined as receiv-
ing a prescription for a medication other than metformin.
The observation period extended from t1 through loss to
follow-up; defined as the 181st day of no contact with any
VHA facility (inpatient, outpatient or pharmacy use), death
or the end of the study (September 30, 2011). Cohort re-
entry was not allowed, therefore, only the first medication
fill which fulfilled inclusion criteria was included.
HbA1c and BMI
Baseline HbA1c or BMI was defined as the value obtained
closest to or at t1. We also collected HbA1c or weight
values in each 30 day time-block after t1 and if none was
available then the last observed post-intensification value
was carried forward for up to 24 months. BMI was calcu-
lated by dividing the weight in kilograms by the square of
height in meters. The median of all available heights was
used for the calculation of BMI. Implausible values were
excluded. This included any HbA1c value <3 and >30 %;
height <48 and >90 in.; and weight <50 and >700 lb.
Covariates
Study covariates were collected from 24 months preced-
ing t1 and values closest to t1 are reported (Additional
file 1: Table S1). Covariates included: age, sex, race
(white, black, other), fiscal year, indicators of healthcare
utilization (hospitalization within last year, number of
outpatient visits), physiologic variables (blood pressure,
creatinine, HbA1c, low density lipoprotein levels, pres-
ence of proteinuria, and body mass index), duration of
monotherapy before intensification of diabetes regimen
(diabetes duration), selected medications, smoking, and
presence of co-morbidities.
Statistical analysis
We tracked diabetes medications on a day by day basis
and evaluated when a prescription occurred for any
hypoglycemic medication after t1. We described the pro-
portion of metformin initiators who changed therapy at
each time point after t1 and the most common regi-
mens. Patterns of medications use are shown from t1
onward in stacked bar plots.
Using descriptive statistics, medians and interquartile
ranges, we examined demographics of the population
who intensified metformin monotherapy and those who
did not intensify metformin therapy by 48 months after
metformin initiation.
To explore changes in HbA1c and BMI, we plotted
the monthly median values of HbA1c and BMI of inten-
sified regimens with 95 % confidence intervals using the
maximum Harrell-Davis standard error over time [22].
We evaluated HbA1c and BMI using two approaches for
medication use classification. First, patients were con-
sidered to remain on their initial intensified regimen
from treatment intensification (t1) through the end of their
follow-up regardless of adherence to drug regimen, medica-
tion changes, or the development of contraindications
(persistent exposure not required). Second, to minimize
exposure misclassification, exposure was defined and
follow-up began at t1 + 6 months and persistent expos-
ure was required [23, 24]. Non-persistence was defined
as a gap of 90 days in which the patient had no anti-
diabetic therapy available. Non persistence to the initial
or intensified regimen could also occur at the time the
patient filled a third anti-diabetic drug. In our population,
allowing 90 days to refill medications approximates ad-
herence of 80 % [25]. Analyses were conducted using R
Statistical Program (R Foundation, available at: http://
www.r-project.org).
Results
There were 323,857 new-users of hypoglycemic medica-
tions (Fig. 1). Of these, 176,556 (55 %) patients initiated
metformin, 140,866 (43 %) initiated sulfonylurea, and
2 % initiated other regimens. Fifty percent (N = 89,057)
of metformin initiators remained on metformin therapy
over a median follow-up 58 months (interquartile range
[IQR] 35, 74). There were 87,499 (49.6 %) patients who
filled a prescription for a regimen other than metformin.
The four most common intensification patterns were the
addition of sulfonylurea (79 %), thiazolidinedione [TZD]
(6 %), or insulin (8 %) or a switch to insulin monother-
apy (2 %). The remaining 6 % included triple therapy,
Glucagon like peptide-1 (GLP-1) receptor agonists and
Dipeptidyl peptidase -4 inhibitors (DPP-4).
Patterns of diabetes medication use over time
Figure 2 panel a depicts the pattern of treatment regi-
mens during 5 years post-intensification in the cohort of
metformin initiators who intensified. All proportions are
calculated based on the initial number of patients that
intensified treatment (time 0 in figure). Thus, the figure
also illustrates that the total number of metformin pa-
tients observed declined over time as patients died, were
lost to follow-up or reached the end of study. Figure 2
panel b is a cross sectional evaluation of each year after
intensification (where the proportion add to 100 %). A
non-trivial proportion stopped all hypoglycemic medica-
tions (~10 % at any time point had no hypoglycemic
filled within the prior 90 days). The use of sulfonylureas
in combination or alone gradually decreased, but insulin
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Fig. 1 Cohort identification and flow
Fig. 2 Diabetes drug intensification patterns among patients who initiated treatment for type 2 diabetes. The total proportion of initiators
decreases over time because patients die or have less than 5 years of follow-up in cohort. Stacked bar plots represent drug patterns after fill of a
medication other than metformin (panel a) Cross sectional proportion of diabetes drugs used among patients alive at each time-point (panel b)
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use remained relatively low. For the 33 % of intensifiers
who remained under follow-up at 5 years, 10.7 % were
using metformin only, 25 % metformin + sulfonylurea,
14 % sulfonylurea only, 20 % other regimens, 15 % insulin
based regimens and 14 % no treatment fill in the prior
90 days.
Characteristics of intensifiers and non intensifiers
Patients who intensified metformin monotherapy were
predominately white males with a median age of 62 years
old. Median time on metformin monotherapy prior to
intensification was 18 months (IQR 6, 37) for addition of
sulfonylurea, 11 months (4,23) for addition of TZDs,
13 months (3,34) for addition of insulin, and 31 months
(18, 49) for switching to insulin. The median follow-up
after intensification was 47 months (26, 66). Patients who
intensified their metformin with an oral agent (either sul-
fonylurea or TZD) had less co-morbidity, fewer outpatient
visits and were less likely to have been hospitalized in the
previous year than those who added insulin or switched to
insulin (Table 2).
Characteristics of metformin patients who did not
intensify therapy by 1, 2 and 4 years of follow-up are
included in Additional file 2: Table S2. Patients who
remained on metformin monotherapy (never intensified)
at 4 years after metformin initiation were slightly older
(median age 67.3 years [60.8, 75.8]) than the majority
of patients who intensified treatment with metformin +
Table 2 Characteristics of patients who intensified metformin therapy
Metformin +Sulfonylurea Metformin + TZD Metformin +Insulin Metformin switch to insulin
N 63,551 4942 6169 1275
Age, years median IQRa 62 (56.5, 70.9) 65 (57.3, 73.9) 61 (54.7, 69.3) 66 (58.4, 76.7)
Male, (%) 96 95 95 96
Race, (%)
White 74 78 68 74
Black 14 10 21 18
Other 4 6 5 5
Months to intensificationa 18 (6, 37) 11 (4, 23) 13 (3, 34) 31 (18, 49)
Systolic Blood Pressure, mmHga 132 (121, 142) 132 (120, 142) 130 (119, 142) 130 (119, 142)
Creatinine, mg/dLa 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 1.1 (0.9, 1.3)
Hospitalized in the last year,% 17.8 17.7 42.9 50.6
Number of outpatient visitsa 6 (4, 11) 5 (3, 9) 7 (4, 13) 6 (3, 12)
Comorbidities, %
Malignancy 9 8 12 16
Liver/Respiratory disease 4 3 10 18
Congestive heart failure 8 6 13 24
Cardiovascular disease 32 33 38 52
Serious Mental illness 28 23 36 38
Arrhythmia 11 10 14 25
COPD/Asthma 17 14 24 32
Smoking 19 14 24 28
Medications
ACE/ARB 71 69 67 52
Antihypertensives 74 73 73 67
Antiarrhythmics 2 2 4 4
Anti-coagulants 13 16 18 24
Statins/lipid lowering drugs 78 77 70 55
Nitrates 11 11 14 13
Aspirin 24 19 30 23
Loop diuretics 13 12 22 24
IQR interquartile range
amedian and interquartile range reported
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sulfonylurea (62 years [56.5, 70.9]). The median HbA1c
among those who remained on metformin monotherapy
at 4 years was 6.4 % [6.0, 6.8], 46 mmol/mol [42, 51] and
BMI was 30.3 (27.1, 34.3). The proportion with specific
comorbidities was generally similar between those who
remained on metformin monotherapy and those who in-
tensified treatment.
HbA1c and BMI
We followed HbA1c and BMI of patients who intensified
to four common regimens after metformin monotherapy
through the end of study or death (persistent exposure
not required). Across these regimens, median HbA1c
values declined from a range of 7.0–7.8 % (53–62 mmol/
mol) at intensification to 6.6–7.0 % (49–53 mmol/mol)
at 1 year, and remained stable up to 3 years afterwards.
Median BMI ranged between 30.5 and 32 kg/m2 at in-
tensification and increased during follow-up very mod-
estly in those who intensified with oral regimens (Fig. 3).
This modest weight gain stabilized by 2 years after treat-
ment intensification. Among those using insulin based
regimens (Fig. 4), weight gain was more pronounced and
yielded between 1.5 and 2 unit increase in BMI (approxi-
mately 3–4 kg weight gain for an average man 5 ft 10 in.).
Weight gain among insulin regimens did not appear to
stabilize by 3 years. A parallel analysis, which censored
patients if they switch regimens (persistent exposure
required), yielded similar results (Additional file 3:
Figure S1).
Discussion
In this study, we report two main findings. First, among
a national cohort of veterans with diabetes, 50 % of metfor-
min initiators intensified therapy by 4 years of follow-up
and while sulfonylurea was the most common addition,
there was an increase in the proportion adding insulin over
time. Second, among those who intensified to the four most
common regimens, the median HbA1c was between 7 and
7.8 % (53–62 mmol/mol) at intensification and 6.6 to 7 %
(49–53 mmol/mol) one year later and remained about 7 %
for the next 3 years. Those on insulin based regimens had a
1–2 kg/m2 weight gain over 3 years.
Our observation of reductions in HbA1c levels with an
associated weight gain among insulin regimens is con-
sistent with results reported by Liu and colleagues [26].
This network meta-analysis of 39 clinical trials (17,860
patients) compared addition of second line medication
classes on HbA1c and BMI outcomes. Trials included
were a minimum of 12 weeks and all less than a year of
follow up, and evaluated metformin with the addition of
either: placebo, sulfonylureas, TZDs, alpha-glucosidase
inhibitors, glinides, DPP-4 inhibitors, or GLP-1 analogues
or insulin. All drug classes reduced HbA1c by 0.6–1.07 %
with no statistically significant differences among classes.
Of note, changes in HbA1c were similar between regi-
mens that added either insulin (biphasic insulin −1.07 %
[−1.46, −0.69 %]; basal insulin −0.88 % [−1.21, −0.56 %]),
or sulfonylureas (−0.82 % [−0.95, −0.70 %]) to metformin.
However, biphasic insulin was noted to have the most
weight gain (3.41 kg [2.04, 4.77]) followed by sulfonylureas
Fig. 3 Median HbA1c and BMI and confidence intervals by intensification group over time: metformin+ sulfonylurea (Panel a); metformin+
thiazolidinedione (Panel b). Patients are allocated into these drug treatment exposures at treatment intensification persistence on medication is
not required. Confidence intervals were calculated using the maximum Harrell-Davis standard error
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(2.17 kg [1.70, 2.65 kg]) and basal insulin (1.38 kg [0.18,
2.60 kg]). In another meta-analysis by Bennett et al. [27]
that included both clinical trials and observational studies,
most add-on regimens had similar efficacy in reducing
HbA1c but also differed in their effects on BMI.
In our cohort, the median HbA1c among those who
intensified metformin (N = 87,499) was 7.4 % (6.7, 8.4)
57 mmol/mol (50, 68) at intensification, while the me-
dian HbA1c was 6.4 % (6.0, 6.8) 46 mmol/mol (42, 51)
among those (N = 73,623) who did not intensify metfor-
min monotherapy by 4 years. Interestingly, patients who
intensified treatment were relatively similar in age and
co-morbidities to those who did not intensify by 4 years.
The American Geriatrics Society and the American Dia-
betes Association recommendations for care of the older
adult with diabetes continue to recommend personalized
HbA1c goals based on co-morbidities with appropriate
goals being 7.5–8 % (58–64 mmol/mol) [28, 29]. VHA
uses an approach which prompts the provider to risk
stratify the patient to determine the HbA1c goals. Using
this strategy many patients within VHA would fall under
glycemic targets of <9 % (<75 mmol/mol) (Table 1) [13].
Further research is needed to determine which patients
might benefit from more aggressive diabetes therapy ra-
ther than applying broad thresholds to all patients [30].
Some limitations to our study should be noted. First,
insulin is available as an over the counter product which
may result in underestimation and misclassification of
insulin users. However, a previous validation of insulin
filled through VHA pharmacies found high accuracy
(positive predictive value = 88 % [80,93], negative predict-
ive value = 95 % [92,97]), suggesting that over the counter
insulin use is infrequent in our system [31]. Second, we
utilized refill data as a proxy for medication taking. Never-
theless, prescription fills are a good proxy for medication
use. Third, veterans may not receive all their care or medi-
cations in VHA facilities resulting in missing laboratory,
weight data or medications, which we partially addressed
through addition of Medicare and Medicaid information
[20, 21]. Fourth, our patients reflect a typical veteran
population, with most patients being white and male and
with a more restricted formulary than many patients seen
in the private sector. Extrapolation of these findings to
other populations warrants caution. Finally, our assess-
ment is purely descriptive and formal comparisons among
intensification groups require accounting for the potential
issues in confounding factors.
Conclusion
In summary, we found that all regimens were associated
with HbA1C declines at 1-year of follow-up, as expected
from clinical trial results. Those prescribed insulin-based
regimens were more likely to have a sustained increase
in weight. Although this study was not designed to directly
compare regimen effectiveness, given the difference in the
treatment patterns, and the similarity in HbA1c reduction,
more emphasis should be placed on identifying oral regi-
mens which are acceptable to patients, affordable, and have
minimal side effects such as weight gain or hypoglycemia.
This finding of increased weight gain among those using in-
sulin in combination with our previous finding of increased
mortality risk [14] should be considered by patients
and clinicians when discussing the risks and benefits of
adding insulin versus a sulfonylurea. Similarly, the HbA1c
level at which patients have their treatment intensified
Fig. 4 Median HbA1c and BMI and confidence intervals by intensification group over time: metformin+ insulin (Panel a); switch to insulin
monotherapy (Panel b). Patients are allocated into these drug treatment exposures at treatment intensification persistence on medication is not
required. Confidence intervals were calculated using the maximum Harrell-Davis standard error
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should be individualized to account for the co-morbidities,
life expectancy and patient age.
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(Panel C); or switch to insulin monotherapy (Panel D). Patients are allocated
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